Citations

Clear

381 citation(s) found for "Gross, MS".

Opioid prescribing trends and pain scores among adult patients with cancer in a large health system
Baum, Laura Van Metre , Soulos, Pamela R. , Ruddy, Kathryn J. , Lerro, Catherine C. , Graham, David J. , Rivera, Donna R. , Liberatore, Mark, Jairam, Vikram , Gross, Cary P. , Park, Henry S. , Ruddy, Kathryn J , Leapman, Michael S , Gross, Cary P , Park, Henry S , KC, Madhav , Jeffery, Molly Moore , Lee, Hana , Leapman, Michael , Dinan, Michaela A.

Mayo Clinic

Cancer | September 22, 2025 | Volume: 131 | Issue: 19 | Pages: No page available

10.1002/cncr.70027 | PMID 40977160 Get It

Abstract Background Opioid stewardship policies could adversely affect pain management for patients with cancer. Yet patients with cancer are also at risk for opioid‐related harms. This study sought to determine trends in opioid prescribing by clinical stratum and pain for patients with cancer from 2016 to 2020. Methods A retrospective study was conducted of opioid‐naive adults with newly diagnosed cancer from 2016 to 2020 ( N = 10,232) in a large Connecticut health system. Logistic regression was used to calculate changes in the predicted probability of opioid prescribing from 2016 to 2020. Two subpopulations were examined: patients treated surgically ( n = 4405) and patients with metastatic cancer ( n = 2158). Flowsheet pain scores for patients with metastatic cancer were used to stratify by no pain (all scores, 0) versus any pain. The main outcomes were new (≥1 prescription in the 0–6 months after diagnosis) and additional (0–6 and 7–9 months) opioid prescriptions. Results A decline was observed in the predicted probability of new (71.1% to 64.6%; p < .001) and additional prescribing (27.2% to 24.2%; p = .07 [not significant]) declined. Among surgical patients, the predicted probability of new opioid prescribing fell (96.0% to 88.6%; p < .001), whereas additional prescribing was stable (13%). For patients with metastatic cancer with pain, new opioid prescribing was stable (56%). For those reporting no pain, the predicted probability of new opioid prescribing declined from 61.6% to 36.1% ( p < .001). Conclusions In the context of widespread policy changes, this study showed a modest decline in new and additional opioid prescribing for patients with cancer. In metastatic cancer, prescribing remained stable for patients reporting pain and declined steeply for those reporting no pain.
Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease
Starr, Philip A. , Shivacharan, Rajat S. , Goldberg, E. Matilda, Tröster, Alexander I. , House, P.A. , Giroux, Monique, Hebb, Adam O. , Whiting, Donald, Leichliter, Timothy, Ostrem, Jill L. , Metman, Leo Verhagen , Karl, Jessica , Siddiqui, Mustafa , Haq, Ihtsham , Moguel‐Cobos, Guillermo , Ponce, Francisco A. , Pahwa, Rajesh, Lyons, Kelly , Buetefisch, Cathrin M. , Luca, Corneliu , Jagid, Jonathan , Revuelta, Gonzalo J. , Takács, István , Pourfar, Michael , Mandybur, George, Zadikoff, Cindy , Khandhar, Suketu M., Sedrak, Mark , Phibbs, Fenna T., Neimat, Joseph S. , Durphy, Jennifer, Ramirez‐Zamora, Adolfo , Pilitsis, Julie G. , Uitti, Ryan J. , Wharen, Robert E. , Park, Michael C. , Vitek, Jerrold L. , Group, INTREPID Study, Galifianakis, Nicholas B. , Schrock, Lauren E. , Farris, Sierra, Nazzarro, Jules M., Haq, Ihtsham , Ramirez-Zamora, Adolfo , Goldberg, Edward, Sani, Sepehr , Tatter, Stephen B. , Machado, André G. , Gostkowski, Michał , Tagliati, Michele , Mamelak, Adam N. , Okun, Michael S. , Foote, Kelly D. , Pahwa, Rajesh , Gross, Robert E. , Takacs, Istvan, Mogilner, Alon Y. , Duker, Andrew , Rosenow, Joshua M. , Group, INTREPID Study, Luciano, Marta San , Cooper, Scott E.

Mayo Clinic

JAMA Neurology | September 15, 2025 | Volume: 82 | Issue: 11 | Pages: 1181

10.1001/jamaneurol.2025.3373 | PMID 40952750 Get It

Importance The Implantable Neurostimulator for the Treatment of Parkinson’s Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD). Objective To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD. Design, Setting, and Participants This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor motor function, modified Hoehn and Yahr Scale scores higher than 2, Unified Parkinson’s Disease Rating Scale (UPDRS-III) score of 30 or higher (medication-off state), and 33% or higher improvement in UPDRS-III medication-on score. Intervention Bilateral STN-DBS for moderate to advanced PD. Main Outcomes and Measures Primary outcomes included changes in UPDRS and dyskinesia scores, quality-of-life measures, and safety assessments. Exploratory analyses included medication reduction and DBS association with motor signs. Results A total of 313 patients were enrolled with 191 receiving the DBS system, and 137 participants (72%) completed the study. The study population had a mean (SD) age of 60 (7.9) years, with 139 (73%) male participants. Motor function without medication as measured by UPDRS-III improved from a mean (SD) of 42.8 (9.4) to 21.1 (10.6) at year 1 (51%; 95% CI, 49%-53%; P &amp;lt; .001) and 27.6 (11.6) at year 5 (36%; 95% CI, 33%-38%; P &amp;lt; .001). Activities of daily living without medication as measured by UPDRS-II improved from a mean (SD) of 20.6 (6.0) to 12.4 (6.1) at year 1 (41%; 95% CI, 38%-42%; P &amp;lt; .001) and 16.4 (6.5) at year 5 (22%; 95% CI, 18%-23%; P &amp;lt; .001). Dyskinesia scores decreased from 4.0 (5.1) to 1.0 (2.1) at year 1 (75%; 95% CI, 73%-75%; P &amp;lt; .001) and to 1.2 (2.1) at year 5 (70%; 95% CI, 63%-75%; P &amp;lt; .001). The levodopa equivalent dose was reduced by 28% at year 1, remaining stable at year 5 (28%; 95% CI, 26%-31%; P &amp;lt; .001). The most common serious adverse event was infection (9 participants). Ten deaths were reported, none related to the study. Conclusions and Relevance Although STN-DBS outcomes declined slightly, possibly due to the progressive nature of the disease, patients with PD sustained significant improvement in motor and activities of daily living scores, along with a stable reduction in anti-parkinsonian medication over the 5-year follow-up period.
Flawed Benchmarks and Biased Cohorts: Reassessing the Evidence for CP ‐ GEP (Merlin) Versus 31‐ GEP (
Bellomo, Domenico , Gross, Christian, Pazhava, Ani , Perniciaro, Charles , Dwarkasing, Jvalini, Meves, Alexander , Gross, Christian

Mayo Clinic

International Journal of Dermatology | August 5, 2025 | Volume: 65 | Issue: 1 | Pages: 12-14

10.1111/ijd.70000 | PMID 40761084 Get It

What Is the Appropriate Sample Size in Human Cadaveric Studies? A Quantitative Review of 770 Articles
Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R. , Kikuchi, Keishiro, Kim, Chung Yoh , Ono, Kisho , D'Antoni, Anthony, Komune, Noritaka , Kitagawa, Norio , Kim, Hee‐Jin , Loukas, Marios , Watanabe, Koichi , Tubbs, R. Shane , Iwanaga, Joe , Obata, Kyoichi , Kato, Tomotaka , Samrid, Rarinthorn , Lesser, Emma R , Kim, Chung Yoh , Ono, Kisho , Komune, Noritaka , Tabira, Yoko , Hur, Mi-Sun , Kim, Hee-Jin , Loukas, Marios , Watanabe, Koichi , Iwanaga, Joe , Cardona, Juan J. , Kikuchi, Keishiro , D’Antoni, Anthony V. , Tabira, Yoko

Mayo Clinic

Clinical Anatomy | July 22, 2025 | Volume: 39 | Issue: 1 | Pages: 14-19

10.1002/ca.70007 | PMID 40692167 Get It

ABSTRACT Determining an appropriate sample size in human cadaveric studies remains a long‐standing and unresolved challenge. Unlike other basic science fields, anatomical research is constrained by factors such as limited human donor availability, cultural considerations, and ethical restrictions. Despite these limitations, researchers are often asked to justify sample sizes, yet no standardized guidelines currently exist. To quantitatively assess sample sizes in recent human cadaveric studies and propose evidence‐based recommendations for future research, a PubMed search was conducted on February 26, 2024, using the term human cadaveric study . The articles published in 2023 and 2024 were screened, yielding 770 eligible studies. Data extracted included the total sample size, number of classified groups, and journal impact factor (IF). Descriptive statistics, linear regression, and correlation analyses were performed. Continuous variables were summarized using medians and interquartile ranges (IQR). The median sample size was 11.5 (IQR: 7–20), and 47.9% of studies used 10 or fewer specimens. The median number of classified groups was 3 (IQR: 2–4). Linear regression showed that studies dividing specimens into 2–6 groups often failed to meet the recommended sample size per group based on regression modeling. No significant correlation was found between sample size and journal IF ( r = −0.062, p = 0.115). Most cadaveric studies rely on small sample sizes due to inherent constraints, yet many still attempt a subgroup analysis without sufficient statistical power. Although flexibility is essential in anatomical research, we recommend a minimum total sample size of 10 for basic studies and at least five samples per group for those involving classification. Cadaveric sample size alone does not predict journal impact, highlighting the importance of methodological rigor over quantity.
O-039 Consortium for dural arteriovenous fistula outcomes research (CONDOR): endovascular treatment of tentorial dural arteriovenous fistulae
Hallak, Hana , Chalouhi, Nohra , Gross, Bradley A. , Satomi, Junichiro, Levitt, M, Sheehan, Jason , Zipfel, Gregory J. , Chatterjee, A, Gross, Bradley , Dijk, J Van, Bulters, Diederik , Hayakawa, M. , Lanzino, Giuseppe , Levitt, M, Alaraj, Ali , Osbun, Joshua W

Mayo Clinic

SNIS 22nd annual meeting oral abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A33-A34

10.1136/jnis-2025-snis.39 Get It

Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer
Flamand, Yael , Quon, Harry , Weinstein, Gregory S., Mehra, Ranee , Garcia, Joaquin J., Kim, Seungwon , O’Malley, Bert W. , Özer, Enver , Ikpeazu, Chukwuemeka , Koch, Wayne M. , Lango, Miriam N. , Smith, Russell K., Karakla, Daniel W., Richmon, Jeremy D. , Burtness, Barbara , Flamand, Yael , Quon, Harry , Mehra, Ranee , Ikpeazu, Chukwuemeka , Gross, Neil D , Bell, R Bryan , Lango, Miriam , Morris, Luc G T , Holsinger, F Chris , Ferris, Robert L , Richmon, Jeremy D , Burtness, Barbara , Garcia, Joaquin J., Bell, R. Bryan , Patel, Mihir R , Holsinger, F. Christopher , Ferris, Robert L.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2025 | Volume: 43 | Issue: 23 | Pages: 2559-2565

10.1200/jco-24-02550 | PMID 40493877 Get It

This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)–associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2 stage III/IV American Joint Committee on Cancer (AJCC) seventh edition p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (arm A); those with clear margins, 2-4 + LN, or ENE ≤1 mm were randomly assigned to 50 Gy (arm B) or 60 Gy (arm C); and those with involved margins, >4 + LN, or >1 mm ENE received weekly cisplatin and 60-66 Gy (arm D). Among 359 evaluable patients, the 54-month progression-free (PFS) and overall survival (OS) were 90.6% (90% CI, 87.2% to 93.1%) and 95.3% (93.0% to 96.9%), respectively. The 54-month PFS by arm was A 93.2% (79.6% to 97.8%; all four recurrences among N1 patients), B 94.9% (89.7% to 97.5%), C 90.2% (82.7% to 94.6%), and D 85.5% (77.5% to 90.8%). The 54-month OS by arm was A 97.1% (85.7% to 99.4%), B 97.9% (93.5% to 99.3%), C 95.1% (90.1% to 97.6%), and D 92.5% (86.9% to 95.7%). PFS or OS did not differ by primary site or smoking history. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS. Among patients with favorable pathologic characteristics, those with N1 disease are at risk of late recurrence without radiation.